Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes
Among the companies that took up the gauntlet was Novo Nordisk, a Danish company which grew out of one founded in 1923 to produce insulin (figure 36)
Agents targeting the glucagon-like peptide-1 receptor (GLP-1R) are effective in managing metabolic conditions associated with obesity, such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic kidney disease (CKD)
It is most critical for patients over 50, perimenopausal or postmenopausal women, and anyone with prior sarcopenia or low baseline muscle mass
What happens if I stop the medication
A thorough medical evaluation is needed to determine if this treatment is a safe and effective choice for you